SOURCE: Oasis Diagnostics Corporation

Oasis Diagnostics Corporation

November 10, 2015 07:00 ET

Oasis Diagnostics® Licenses Innovative Technology for Non-Invasive Saliva-Based Diagnosis of Sleep Disorders

VANCOUVER, WA--(Marketwired - November 10, 2015) - Oasis Diagnostics®, an innovative company focused on the development of a series of proprietary tools for simple saliva sample acquisition and testing announced that it has entered into an agreement to license novel salivary diagnostic technology from scientists working in Denmark, (Drs. Balwant Rai and Jasdeep Kaur) for the detection, monitoring, and diagnosis of sleep disorders.

The unique discovery by the inventors covers a series of salivary biomarkers in oral [saliva] specimens that are modified (up-or-down-regulated) in patients suffering from common sleep disorders such as sleep apnea or sleep deprivation.

Obstructive Sleep Apnea [OSA] is reported to affect over 18 million Americans, according to the National Sleep Foundation¹ and the Harvard Medical School of Sleep Medicine estimates that the economic impact of moderate to severe OSA in the US could be as high as $165 billion². OSA is also associated with a number of serious health risks including sleep deprivation, heart disease, high blood pressure and diabetes, so it is important that technology is made available to detect OSA at an early stage to reduce the burden on an already over-burdened healthcare system.

Commenting on the new license agreement, CEO, Dr. Paul D. Slowey said, "we are very pleased to have gained access to a technology that can facilitate non-invasive diagnosis of sleep disorders in real time." The integration of such a sensitive and specific biomarker technology for sleep disorders with our own proprietary VerOFy® Point-of-Care Testing platform will open up opportunities to detect OSA in clinics, doctors' offices, dental practices and other point-of-care settings using saliva as the preferred sample type. Currently there is a dearth of biomarkers available to diagnose this widespread disorder, while multiple simple opportunities for intervention and treatment exist. Contrary to other biomarkers used for diagnosis of sleep apnea, the biomarkers covered under this agreement are not light sensitive, a feature that will open up the possibility for sleep studies to be performed in multiple settings and not just in purpose built, blacked out "sleep units".

Oasis will work closely with the inventors to file additional patents to protect the technology and work to develop a non-invasive tool for sleep disorders that will deliver immediate results in 20 minutes at the point of care using saliva specimens.

Oasis is also pleased to announce the launch of NeoSal™, a patented tool for oral fluid drugs of abuse collection, through its strategic partner Neogen Corporation. Oasis developed the NeoSal™ device for Neogen, who will be marketing the device on an exclusive basis for drug monitoring purposes in the United States and Canada. Further details on this can be found in the press release issued by Neogen Corporation on July 28th 2015, which is available at the following link:


1. Hublin C, Patrtinen M, Koskenvuo M, Kaprio J. Sleep and Mortality: A Population-Based 22-Year Follow-Up Study. Sleep. 2007; 30: 1245-1253.

2. Sleep Apnea. National Sleep Foundation website. . Accessed January 26, 2015.

3. The Price of Fatigue: The Surprising Economic Costs of Unmanaged Sleep Apnea. Harvard Medical School Division of Sleep Medicine website. Published December 2010. Accessed January 26, 2015.


Oasis Diagnostics® specializes in the development of saliva collection devices and test systems that includes an array of devices for the standardized collection of oral fluids and testing of specimens both in the laboratory and at the point-of-care. Currently the company offers the Versi•SAL® and Super•SAL™ Saliva Collection Devices for standardized oral fluid collection, VerOFy®, a rapid point-of-care testing platform device, DNA•SAL™, a novel collection tool for the harvesting of DNA from saliva for applications such as PCR, genotyping and genome-wide association studies, Accu•SAL™, a tool for collection of saliva for abused drug testing and RNAPro•SAL™ and Pure•SAL™ new devices for the simple and non-invasive collection of RNA and proteins. Novel devices for pediatric saliva collection [Pedia•SAL™] and Micro•SAL™ [small animal collection] are in the validation stage at this time.

In addition, Oasis Diagnostics® is the exclusive representative for genomic products from ViennaLab Diagnostics (Vienna, Austria) and Operon S.A. (Zaragoza, Spain) in North America.

Oasis holds an exclusive license to technologies for the collection and subsequent testing of saliva for Alzheimer's disease and Parkinson's disease and is the recipient of a Phase II SBIR Grant from the National Institutes of Health [NIH] for the development of a rapid, saliva based point-of-care test for the stress hormone cortisol.

Contact Information

  • Contact: Paul D Slowey PhD CEO
    Oasis Diagnostics® Corporation
    15720 NE 31st Avenue, Vancouver WA 98686
    Phone: (360) 546-1563; E-mail: